Weakness in Aratana Shares An 'Excellent' Entry Point
Aratana Therapeutics Inc seems to be firing on all cylinders and the recent weakness in shares represents an attractive buying opportunity, Lake Street Capital Markets’ Carl Byrnes said in a report. He reiterated a Buy rating on the company, with a price target of $15.
Analyst Carl Byrnes expressed optimism regarding Aratana Therapeutics being able to emerge as a leading innovator in the companion animal veterinary medicines market. He added, “We perceive the recent weakness as a major buying opportunity.”
Commercialization On The Horizon
Byrnes mentioned that Aratana Therapeutics appears to be on track to commercializing four NCEs this year: ◾ Galliprant: Approved in March - For control of inflammation and pain associated with osteoarthritis ◾ Entyce: Approved in May - A breakthrough first-in-class therapeutic for appetite stimulation ◾ Nocita: ADUFA approval date of August 28 - Liposomal bupivacaine that provides for long duration post-operative pain management ◾ AT-014 - An immune-vaccine for post-operative treatment of osteosarcoma
Galliprant, Entyce and Nocita seem to be well positioned to becoming blockbuster therapies in the companion animal segment, the analyst added.
Next up is a unique veterinary drug play that has just started to move. The name of this ~$260 million market cap concern is Aratana Therapeutics (NASDAQ:PETX). The company's first drug "Galliprant" was approved early this year which was followed by a large collaboration deal to market and distribute that drug that will mean a faster rollout.
The company's second drug "Entyce" was approved in May and its third drug "Nocita" should be approved by the end of the year. With three drugs soon to be on the market, plenty of cash in the till and a large collaboration deal in place; this is an undervalued and overlooked concern in an unfollowed part of the market. Lake Street reiterated a Buy rating with a $15 price target in July, this seems more representative of the company's fair value over time. For more detailed research on Aratana, click here for recent article. seekingalpha.com/article/3978240-6-biopharma-stock-dogs-good-thing-investors
Under: Been on the sidelines for a bit holding (building) cash. Now that "BIGLEY" has rolled out the tax plan its time to jump in.
Dec 21, 2017 19:06:02 GMT -6
martyc: Looks like you are buying Msft again!
Dec 15, 2017 11:23:29 GMT -6
martyc: The news that Trump called Rupert to congratulate him sure seems to indicate that this is heading to approval
Dec 15, 2017 11:22:23 GMT -6
Under: DIS finally getting some traction.?
Dec 14, 2017 17:08:45 GMT -6
martyc: I took an entry level position in DIS. Will add eventually to overweight when it becomes clearer that the deal will go thru. Can't believe how well positioned they will be. 60% Hulu. 20% of content watched on NFLX they can pull. More in thread
Dec 14, 2017 11:05:16 GMT -6
Under: Great posts on $DIS
Dec 13, 2017 17:50:49 GMT -6
Under: $ROKU Citron on a war path.
Nov 28, 2017 15:11:20 GMT -6
Under: $HAS takeover bid for $MAT?
Nov 10, 2017 16:16:07 GMT -6
martyc: Not looking like the market will provide any discounted opp for SGMO. Call was just too professional and all signs indicate they are on a great path for commercialization. Happy with core but wish I had some trading shs
Nov 10, 2017 9:04:05 GMT -6
martyc: For anyone looking to find an entry point into SGMO, I'm almost hoping is sells off in next few days so I can add more. They are really clicking but the fact they haven't signed new deals might cause some to exit. Watching as I have room for trading shs
Nov 9, 2017 18:28:09 GMT -6
martyc: Been an interesting ride so far. I figured the Bears would be about this good but hoped the O wouldn't look so lame. Another building yr but still possible to get to 8-8 IMO
Nov 9, 2017 18:26:08 GMT -6
Under: whats up with your Bears this year Marty?
Nov 9, 2017 17:35:25 GMT -6
martyc: Hope you were long ROKU. I wanted to see Q first so missed out
Nov 9, 2017 7:08:53 GMT -6